News

IQISH technology, based on Dako’s fast IQISH hybridization buffer chemistry, reduces the evaluation time from two days to three and a half hours, facilitating quick initiation of the

The study observed a statistically significant relationship between injected dose and antitumor activity of the investigational agent. ATLAB medical affairs head Pr. Jean-François Chatal said, "ATL101 shows a

According to the deal, Heptares will produce stabilized receptors (StaRs) for MorphoSys proposed GPCR disease target set. The Ylanthia antibody library will then be applied by MorphoSys to

Tresiba is the new once-daily basal insulin with an ultra-long duration of action for the treatment of type 1 and type 2 diabetes. Tresiba successfully achieved equivalent reductions

Coyote is expected to file IND application for CNS-102 for amyotrophic lateral sclerosis (ALS) therapy in the fourth quarter of 2013 and commence a Phase 1 study in

Production of MU1140 using fermentation has also lead to the discovery of a new purification process for the product, according to Oragenics. Lantibiotic MU1140 is intended to be

The supplement that is expected to last for 24 to 48 hours is developed to improve endurance, strength, and energy in males. Hokutou CEO Eugene Collings said the

The final step in the solubilization partnership between the companies is expected to aid Dow to commercially supply solubility enabling excipients. Dow senior R&D director Bob Maughon said,

According to the deal, Bristol-Myers will earn $438m upfront payment from Reckitt Benckiser for the exclusive rights to sell, distribute and market the products for a period of